奥沙香豆素 | 15301-80-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 中文名称: 奥沙香豆素
• 英文名称: 6,7-bis-(2-diethylamino-ethoxy)-4-methyl-coumarin
• 英文别名: 6,7-Bis-(2-diaethylamino-aethoxy)-4-methyl-cumarin；Oxamarin；6,7-bis[2-(diethylamino)ethoxy]-4-methylchromen-2-one
• CAS: 15301-80-1
• 化学式: C₂₂H₃₄N₂O₄
• 分子量: 390.523
• InChiKey: KDZPIXVLPYVHDO-UHFFFAOYSA-N

物化性质

• 熔点：
  47-49°C
• 沸点：
  bp0.5 195°
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  28
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  51.2
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 海关编码：
  2932209090

反应信息

• 作为反应物：
  描述：

  奥沙香豆素 、 碘甲烷 在 乙醇 作用下， 生成 6,7-bis-[2-(diethyl-methyl-ammonio)-ethoxy]-4-methyl-coumarin; diiodide
  参考文献：
  名称：

  Massarani, Farmaco, Edizione Scientifica, 1957, vol. 12, p. 691,693

  摘要：

  DOI：
• 作为产物：
  描述：

  4-甲基七叶苷原 、 N,N-二乙基氯乙胺 在 sodium hydroxide 、 丙酮 作用下， 生成 奥沙香豆素 、 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  Massarani, Farmaco, Edizione Scientifica, 1957, vol. 12, p. 691,693

  摘要：

  DOI：

文献信息

• Pharmaceutical preparation comprising an active dispersed on a matrix
  申请人：——

  公开号：US20040058896A1

  公开（公告）日：2004-03-25

  The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

  本发明涉及制药技术领域，描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Apparatus and method for marking tissue
  申请人：ETHICON ENDO-SURGERY, INC.

  公开号：EP1579878A1

  公开（公告）日：2005-09-28

  The present invention includes methods and materials for implantable devices (markers) which are disclosed for permanently marking the location of a biopsy or surgery for the purpose of identification. The devices are remotely delivered, preferably percutaneously. Visualization of the markers is readily accomplished using various state of the art imaging systems. Preferred visualization is through MRI, X-ray and ultrasound. The markers function to provide evidence of the location of the lesion after the procedure is complete for reference during future examinations or procedures.

  本发明包括可植入装置（标记物）的方法和材料，这些装置用于永久标记活检或手术的位置，以便识别。这些装置可远程投放，最好是经皮投放。标记的可视化可通过各种最先进的成像系统轻松实现。最好通过核磁共振成像、X 射线和超声波进行观察。标记的作用是在手术完成后提供病变位置的证据，供今后检查或手术时参考。
• Methods and compositions for treating conditions associated with an abnormal inflammatory responses
  申请人：First Wave Bio, Inc.

  公开号：US10292951B2

  公开（公告）日：2019-05-21

  This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

  本公开的化学实体（例如，具有线粒体解偶联剂活性的化合物或其药学上可接受的盐和/或水合物和/或共晶体；例如，化合物，如烟酰胺或其药学上可接受的盐和/或水合物和/或共晶体；例如、化合物，如尼可刹米类似物，或其药学上可接受的盐和/或水合物和/或共晶体），这些化合物可用于治疗受试者（如人类）中以异常炎症反应（如炎症性肠病）为特征的病理学的一种或多种症状。本公开内容还包括组合物以及使用和制造组合物的其他方法。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。